The role of of laccase in lignification

DM O'Malley, R Whetten, W Bao, CL Chen… - The Plant …, 1993 - Wiley Online Library
The enzymatic mechanism of monolignol polymerization in lignin biosynthesis is not known,
although it has been the subject of significant interest for more than 60 years. Peroxidase …

[HTML][HTML] A comprehensive overview of radioguided surgery using gamma detection probe technology

SP Povoski, RL Neff, CM Mojzisik, DM O'Malley… - World journal of surgical …, 2009 - Springer
The concept of radioguided surgery, which was first developed some 60 years ago, involves
the use of a radiation detection probe system for the intraoperative detection of …

Low-grade serous ovarian cancer: state of the science

…, H Mahdi, KK Wong, A Covens, DM O'Malley… - Gynecologic …, 2020 - Elsevier
In January 2019, a group of basic, translational, and clinical investigators and patient
advocates assembled in Miami, Florida, to discuss the current state of the science of low-grade …

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …

…, MA Gancedo, PC Fong, JC Goh, DM O'Malley… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-…

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

…, RL Coleman, AV Tinker, DM O'Malley… - The lancet …, 2017 - thelancet.com
Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian
carcinomas with homologous recombination deficiency. Along with BRCA1 and BRCA2 (BRCA) …

Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology

…, S Lele, L Martin, UA Matulonis, DM O'Malley… - Journal of the National …, 2016 - jnccn.org
This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common
ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and …

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

…, LT Vo, E Mann, JD Isaacson, L Maloney, DM O'Malley… - Cancer discovery, 2019 - AACR
BRCA reversion mutations are detected in cfDNA from platinum-resistant or platinum-refractory
HGOC and are associated with decreased clinical benefit from rucaparib treatment. …

[HTML][HTML] Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: results from the KEYNOTE-158 study

DM O'Malley, GM Bariani, PA Cassier… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Pembrolizumab demonstrated durable antitumor activity in patients with
previously treated, advanced microsatellite instability–high or mismatch repair–deficient (MSI-H/…

Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology

…, M McHale, K McLean, DS Miller, DM O'Malley… - Journal of the National …, 2021 - jnccn.org
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United
States and is the country’s fifth most common cause of cancer mortality in women. A major …

Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic …

…, BG Kim, K Fujiwara, KS Tewari, DM O'Malley… - The Lancet …, 2017 - thelancet.com
Background Platinum-based chemotherapy doublets are a standard of care for women with
ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed …